INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)				Attorney Docket No. <b>056291-5296</b>		Application No. 10/586,954	
				Applicants: David Michael ANDREWS et al.			
PTO Form 1449 March 23, 2009			Filing Date: July 25, 2006		Group Art Unit: 1624		
			U.S. PA	TENT DOCUMENTS			
Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
						<del>                                     </del>	
				·····			
		***************************************	FOREIGN	PATENT DOCUMEN	TS		
		Document No.	Date	Country	Class	Sub-Class	Translation
	1.	WO 2004/005282	January 15, 2004				
	2.	WO 2005/068452	July 28, 2005	WIPO			
· · · · · ·	3. 4.	WO 2007/040436 WO 2008/002244	April 12, 2007 January 3, 2008	WIPO WIPO			
	5.	WO 2008/002244 WO 2008/002245	January 3, 2008	WIPO			
				ling Author, Title, Date			
	6. Anderson et al. "Imidazo[1,2-a]pyridines: A potent and selective class of cyclin-dependent kinase inhibitors in						
	****	through structure-based hybridisation" Bioorganic & Medicinal Chemistry Letters 13(18):3021-3026 (2003).					
	7.	7. Byth et al. "Imidazo[1,2-a]pyridines. Part 2: SAR and optimisation of a potent and selective class kinase inhibitors" Bioorganic & Medicinal Chemistry Letters 14(9): 2245-2248 (2004).					
	8. Byth et al. "Imidazo[1,2-b]pyridazines: a potent and selective class of cyclin-dependent kinase inhibitors" Bioon & Medicinal Chemistry Letters 14(9): 2249-2252 (2004).  9. Byth et al. "The cellular phenotype of AZ703, a novel selective imidazo[1,2-a]pyridine cyclin-dependent kinase inhibitor" Molecular Cancer Therapeutics 5(3):655-664 (2006).						shibitors" Bioorganic
							pendent kinase
					······		
						1,000	****
						****	
			——————————————————————————————————————				
	···			······			
					****		
Examiner			Date C	onsidered			
Examiner: conformance	Initial e and	if reference considered, not considered. Include	whether or not citate copy of this form wi	ion is in conformance w th next communication	ith MPEP 609; to applicant.	draw line thro	ough citation if not in